Evidence map›Paper›PMID 21139689›Full record

ArticleMolecular vision2010

A serine-type protease activity of human lens βA3-crystallin is responsible for its autodegradation.

R Gupta, J Chen, O P Srivastava

Open access · greenAbstract read
In one paragraph

Article in Molecular vision, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. A Complex Lens for a Complex Eye.Integrative and comparative biology · 2017
    Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

R GuptaDepartment of Vision Sciences, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
J Chen
O P Srivastava
University of Alabama at Birmingham · US

Funding

Visual Phenotyping CoreP30EY003039 · NEI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI LAWRENCE C SINCICH · 1985 to 2026
$16.9M
PROTEINASE INHIBITORS &CRYSTALLIN FRAGMENTS IN CATARACTR01EY006400 · NEI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SRIVASTAVA, OM PRAKASH · 1985 to 2018
$5.6M
Noninvasive Visualization and Analysis of Organ Systems using OCT and Digital FunS10RR026887 · NCRR · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI PITTLER, STEVEN J · 2010 to 2010
$275k
NCRR NIH HHS S10 RR026887NCRR NIH HHS S10RR026887NEI NIH HHS EY06400NEI NIH HHS P30 EY003039NEI NIH HHS P30-EY03039NEI NIH HHS R01 EY006400
6 · The paper itself

Abstract

purposeThe purpose of the study was to determine whether the autodegradation of human βA3-crystallin is due to its intrinsic protease activity.

methodsRecombinant His-tagged human βA3-crystallin was expressed in E. coli and purified by a Ni+2-affinity column chromatographic method. To determine protease activity, the purified crystallin was incubated for 24 h with either sodium deoxycholate, Triton X-100, or CHAPS {3-[(3-Cholamidopropyl) dimethylammonio]-1-propanesulfonate} and with benzoyl DL-arginine p-nitroanilide (BAPNA), a colorimetric protease substrate. The autodegradation of the crystallin at 0 h and 24 h on incubation at 37 °C with and without detergents (CHAPS/Triton X-100) was also determined by sodium dodecylsulfate-PAGE (SDS-PAGE) method. To examine whether the autodegradation of the crystallin was due to its protease activity, the crystallin was incubated with inhibitors of serine-, metallo- and cysteine-proteases. The binding of the intact βA3-crystallin and its autodegradation products to FFCK [5-carboxyfluorescenyl-1-phenylalaninyl-chloromethyl ketone], an analog of TPCK [1-Chloro-3-tosylamido-4-phenyl-2-butanone, a chymotrypsin-type serine protease inhibitor] was also determined by their incubation followed by SDS-PAGE and scanning for fluorescence using a Typhoon 9400 scanner.

resultsβA3-crystallin protease activity showed activation in the presence of CHAPS but not in presence of Triton X-100. Upon incubation of βA3-crystallin for 24 h with CHAPS or sodium deoxycholate and BAPNA as a substrate, a time-dependent increase in the Arg-bond hydrolyzing activity was observed. SDS-PAGE analysis exhibited autodegradation products with Mr of 22, 27 and 30 kDa, which on partial NH2-terminal sequencing showed cleavage of Lys17-Met18, Gln4-Ala5 and Thr-Gly (in the NH2-terminal His-tag region) bonds, respectively. Almost no autodegradation of the βA3-crystallin occurred during its incubation alone or with CHAPS plus serine protease inhibitors (phenylmethylsulfonyl fluoride [PMSF], approtinin, and chymostatin). In contrast, the autodegradation occurred in the presence of metallo-protease inhibitors (EDTA and EGTA) and cysteine protease inhibitors (E-64, N-methylmaleimide and iodoacetamide). The βA3-crystallin also exhibited binding to FFCK, suggesting existence of a chymotrypsin-type active site in the βA3-crystallin protease.

conclusionsThe results suggested that a serine-type protease activity of βA3-crystalllin was responsible for its autodegradation. The specific bonds cleaved during autodegradation (Gln4-Ala5 and Lys17-Met18), were localized in the NH2-terminal arm of βA3-crystallin.

Indexed as

Protein Processing, Post-Translationalbeta-Crystallin A ChainCholic AcidsChromatography, AffinityDeoxycholic AcidDetergentsElectrophoresis, Polyacrylamide GelEnzyme ActivationFluorescenceHumansLens, CrystallineProtease InhibitorsRecombinant ProteinsSerine Proteases3-((3-cholamidopropyl)dimethylammonium)-1-propanesulfonatebeta-Crystallin A ChainCholic AcidsCRYBA1 protein, humanDeoxycholic AcidDetergentsProtease InhibitorsRecombinant ProteinsSerine Proteases

Identifiers

PMID21139689
PMCPMC2994418
OpenAlexW37370850

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.